CEFROXADINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H19N3O5S
Molecular Weight	365.404
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC(OC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CCC=CC3)C(O)=O

InChI

InChIKey=RDMOROXKXONCAL-UEKVPHQBSA-N

InChI=1S/C16H19N3O5S/c1-24-9-7-25-15-11(14(21)19(15)12(9)16(22)23)18-13(20)10(17)8-5-3-2-4-6-8/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H19N3O5S
Molecular Weight	365.404
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6998373

Cefroxadine is an antibiotic developed for the treatment of bacterial infectious diseases caused by gram-negative and gram-positive organisms. The information about drug status is unavailable and is supposed to be "discontinued", however it may be manufactured in Italy by Novartis.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial infections 234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6998373	Curative		Approved 8429	ORASPOR Approved Use Unknown

PubMed

Title	Date	PubMed
[Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].	2004 Dec	15747584
A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.	2006 Feb 13	16137854

Patents

Sample Use Guides

In Vivo Use Guide

The daily dosage of 1000mg should be divided into 2 fractions and should be taken after breakfast and after supper.

Route of Administration: Oral

In Vitro Use Guide

The spectrum of antibacterial activity of cefroxadine against gram-positive and gram-negative bacteria was studied. About 0.005 ml of diluted culture was inoculated by Micro-planter onto agar plates containing a series of serial twofold dilutions of a drug. The concentration of the drug required to inhibit the growth of 50% of the total number of tested E. coli strains (MIC50) was 3.13 to 6.25 ug/ml. The MIC50 of cefroxadine against K. pneumoniae strains was 3.13 to 6.25 ug/ml.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:01:29 GMT 2023` Edited by `admin` on `Sat Dec 16 16:01:29 GMT 2023`
Record UNII	B908C4MV2R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFROXADINE

Official Name

English

CEFROXADINE [MART.]

Common Name

English

CEFROXADINE [MI]

Common Name

English

cefroxadine [INN]

Common Name

English

CEFTHAN-DS

Brand Name

English

Cefroxadine [WHO-DD]

Common Name

English

ORASPOR

Brand Name

English

(6R,7R)-7-[(R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido]-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Systematic Name

English

CGP 9000

Code

English

CGP-9000

Code

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((AMINO-1,4-CYCLOHEXADIEN-1-YLACETYL)AMINO)-3-METHOXY-8-OXO-, (6R-(6A,7B(R*)))-

Systematic Name

English

CEFROXADINE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C357